Healthcare News | BioTuesdays by Kilmer Lucas IR

Executive Moves

John Baumgartner named Lake Street’s head of capital markets

Lake Street Capital Markets has named John Baumgartner as its head of capital markets, responsible for overseeing marketing, pricing, and distribution of its capital raising activities. Mr. Baumgartner began his career...

July 12, 2019

Markets

Stifel ups Rhythm Pharma to buy; PT held at $34

Stifel upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) to “buy” from “hold” but maintained its price target at $34, saying the stock is at an attractive entry point ahead of near-term Phase 3 results. The stock closed at...

July 12, 2019

Developments

Kadmon Holdings doses first patient in Phase 2 systemic sclerosis trial

Kadmon Holdings (NYSE:KDMN) dosed the first patient in its Phase 2 clinical trial of KD025 in patients with diffuse cutaneous systemic sclerosis (SSc). SSc is a chronic immune disease characterized by fibrosis of the...

July 11, 2019

Developments

GMP adds Zenabis Global to Best Ideas list

GMP Securities added Zenabis Global (TSX:ZENA) to its Best Ideas list, saying its sees the company becoming a top five Canadian licensed producer of cannabis but with a valuation well below most of its peers. Analyst...

July 10, 2019

Developments

Profound Medical sells first TULSA-PRO system in Japan

Profound Medical (TSX:PRN; OTCQX:PRFMF) sold its first TULSA-PRO system to Hokuyu Hospital in Sapporo through Japan’s Pharmaceutical and Medical Device (PMD) Act’s expanded access program. Japan’s Pharmaceutical...

July 10, 2019

Developments

Trovagene initiates Phase 1b/2 trial of ovansertib in colorectal cancer

Trovagene (NASDAQ:TROV) began enrollment for its Phase 1b/2 study of onvansertib for the treatment of patients with metastatic colorectal cancer (mCRC). The trial will assess the safety and efficacy of onvansertib, in...

July 9, 2019

Developments

Titan Pharma and CVS Caremark enter Probuphine distribution agreement

Titan Pharmaceuticals (NASDAQ:TTNP) signed a specialty product distribution agreement with CVS Caremark, a subsidiary of CVS Health, further expanding access to treatment with Probuphine implant, Titan’s novel...

July 9, 2019

Executive Moves

IDEAYA Biosciences makes three appointments to management team

IDEAYA Biosciences (NASDAQ:IDYA) promoted Paul Stone to CFO, Andres Briseno to VP finance, and Mick O’Quigley to VP development operations. Continuing his role as IDEAYA’s principal financial and accounting...

July 9, 2019

Executive Moves

ORIC Pharma names Lori Friedman as CSO

Closely-held ORIC Pharmaceuticals appointed Lori Friedman as CSO, responsible for leading ORIC’s research and preclinical development efforts.

July 9, 2019

Developments

Zenabis submits site evidence package to Health Canada for Langley facility

Zenabis Global Inc. (TSX:ZENA)submitted its site evidence package to Health Canada for the first phase of Site A at its Zenabis Langley plant.

July 9, 2019

Markets

Maxim cuts PTs on five biotech stocks

Maxim Group reduced price targets for five biotech stocks, citing data troughs, financing conditions and political factors, which may be further compounded by a lack of catalysts and increasing operating expenses...

July 9, 2019

Developments

Pulmatrix opens three Phase 2 clinical trial sites for inhaled anti-fungal

Pulmatrix (NASDAQ:PULM) activated three U.S. sites for its Phase 2 clinical trial of pulmazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The primary objective of the...

July 9, 2019

John Baumgartner named Lake Street’s head of capital markets

Stifel ups Rhythm Pharma to buy; PT held at $34

Kadmon Holdings doses first patient in Phase 2 systemic sclerosis trial

GMP adds Zenabis Global to Best Ideas list

Profound Medical sells first TULSA-PRO system in Japan

Trovagene initiates Phase 1b/2 trial of ovansertib in colorectal cancer

Titan Pharma and CVS Caremark enter Probuphine distribution agreement

IDEAYA Biosciences makes three appointments to management team

ORIC Pharma names Lori Friedman as CSO

Zenabis submits site evidence package to Health Canada for Langley facility

Maxim cuts PTs on five biotech stocks

Pulmatrix opens three Phase 2 clinical trial sites for inhaled anti-fungal

General

More